Table 1.

Safety of CXL in thin corneas

Author, year	No. of eyes	Surgical procedures	Follow up (months)	VA and topography changes	Endothelial loss	Other complications
Kymionis, et al. 2012 [38]	14	Conventional	12	UDVA and CDVA improved, Kmean reduced	Yes	No
Hafezi, et al. 2009 [30]	20	Hypoosmolar riboflavin solution	6	Kmax stable or reduced	–	No
Raiskup and Spoerl 2011 [42]	32	Hypoosmolar riboflavin solution	12	CDVA and Kmax stable	–	No
Wu, et al. 2014 [43]	15	Hypoosmolar riboflavin solution	12	1 eye lost 1 line CDVA, the rest remained stable or improved, Kmax and Kmin reduced	No	No
Soeters and Tahzib 2015 [48]	13	Hypoosmolar riboflavin solution	12	CDVA improved, Kmax, Kmin and Kmean remain stable	No	No
Gu, et al. 2015 [45]	8	Hypoosmolar riboflavin solution	3	CDVA stable, Kmax stable	Yes	No
Filippello, et al. 2012 [28]	20	Transepithelial CXL	18	UDVA and CDVA improved, keratometry values decreased	No	No
Spadea and Mencucci 2012 [31]	16	Transepithelial CXL	6–12	UDVA and CDVA improved, Kmax reduced	No	No
Kymionis, et al. 2009 [29]	2	Custom epithelial debridement	9	Topography stable	No	No
Kaya, et al. 2011 [69]	2	Custom epithelial debridement	1	–	–	No
Mazzotta and Ramovecchi 2014 [70]	10	Custom epithelial debridement	12	UDVA, CDVA stable, Kmean reduced	No	No
Jacob, et al. 2014 [73]	14	Contact lens-assisted	6–7	CDVA stable, Kmax stable	No	No

K _max = Maximum keratometric reading, K _min = Minimum keratometric reading, K _mean = Mean keratometry reading, SimK = Simulated keratometry, VA = Visual acuity, UDVA = Uncorrected distance visual acuity, CDVA = Corrected distance visual acuity